Chemotherapeutic Dose Scheduling Based on Tumor Growth Rates Provides a Case for Low-Dose Metronomic High-Entropy Therapies

Cancer Research - Tập 77 Số 23 - Trang 6717-6728 - 2017
Jeffrey West1, Paul K. Newton1,2
11Department of Aerospace and Mechanical Engineering, University of Southern California, Los Angeles, California.
22Department of Mathematics, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California.

Tóm tắt

Abstract We extended the classical tumor regression models such as Skipper's laws and the Norton–Simon hypothesis from instantaneous regression rates to the cumulative effect over repeated cycles of chemotherapy. To achieve this end, we used a stochastic Moran process model of tumor cell kinetics coupled with a prisoner's dilemma game-theoretic cell–cell interaction model to design chemotherapeutic strategies tailored to different tumor growth characteristics. Using the Shannon entropy as a novel tool to quantify the success of dosing strategies, we contrasted MTD strategies as compared with low-dose, high-density metronomic strategies (LDM) for tumors with different growth rates. Our results show that LDM strategies outperformed MTD strategies in total tumor cell reduction. This advantage was magnified for fast-growing tumors that thrive on long periods of unhindered growth without chemotherapy drugs present and was not evident after a single cycle of chemotherapy but grew after each subsequent cycle of repeated chemotherapy. The evolutionary growth/regression model introduced in this article agrees well with murine models. Overall, this model supports the concept of designing different chemotherapeutic schedules for tumors with different growth rates and develops quantitative tools to optimize these schedules for maintaining low-volume tumors. Cancer Res; 77(23); 6717–28. ©2017 AACR.

Từ khóa


Tài liệu tham khảo

Hanahan, 2000, Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice, J Clin Invest, 105, 1045, 10.1172/JCI9872

Lien, 2013, Low-dose metronomic chemotherapy: a systematic literature analysis, Eur J Cancer, 49, 3387, 10.1016/j.ejca.2013.06.038

Kerbel, 2004, The anti-angiogenic basis of metronomic chemotherapy, Nat Rev Cancer, 4, 423, 10.1038/nrc1369

Browder, 2000, Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer, Cancer Res, 60, 1878

Klement, 2000, Continuous low-dose therapy with vinblastine and vegf receptor-2 antibody induces sustained tumor regression without overt toxicity, J Clin Invest, 105, R15, 10.1172/JCI8829

Axelrod, 2006, Evolution of cooperation among tumor cells, Proc Natl Acad Sci, 103, 13474, 10.1073/pnas.0606053103

Nowak, 1990, Stochastic strategies in the prisoner's dilemma, Theor Popul Biol, 38, 93, 10.1016/0040-5809(90)90005-G

Cover, 2012, Elements of information theory

West, 2016, An evolutionary model of tumor cell kinetics and the emergence of molecular heterogeneity and gompertzian growth, SIAM Rev, 58, 716, 10.1137/15M1044825

West, 2016, The prisoner's dilemma as a cancer model, Converg Sci Phys Oncol, 2, 035002, 10.1088/2057-1739/2/3/035002

Benzekry, 2015, Metronomic reloaded: Theoretical models bringing chemotherapy into the era of precision medicine, Semin Cancer Biol, 35, 53, 10.1016/j.semcancer.2015.09.002

Wodarz, 2014, Dynamics of cancer: mathematical foundations of oncology, 10.1142/8973

Goldie, 2009, Drug resistance in cancer: mechanisms and models

Frei, 1980, Dose: a critical factor in cancer chemotherapy, Am J Med, 69, 585, 10.1016/0002-9343(80)90472-6

Skipper, 1964, Experimental evaluation of potential anticancer agents. xxi. on the criteria and kinetics associated with curability of experimental leukemia, Cancer Chemother Rep, 35, 1

Perry, 2008, The chemotherapy source book

Norton, 1977, Growth curve of an experimental solid tumor following radiotherapy, J Natl Cancer Inst, 58, 1735, 10.1093/jnci/58.6.1735

Norton, 1977, Tumor size, sensitivity to therapy, and design of treatment schedules, Cancer Treat Rep, 61, 1307

Traina, 2010, Optimizing chemotherapy dose and schedule by norton-simon mathematical modeling, Breast Dis, 31, 7, 10.3233/BD-2009-0290

Held, 2006, Dose-intensified treatment of advanced-stage diffuse large b-cell lymphomas, Semin Hematol, 43, 221, 10.1053/j.seminhematol.2006.07.003

Prokopiou, 2015, A proliferation saturation index to predict radiation response and personalize radiotherapy fractionation, Radiat Oncol, 10, 1, 10.1186/s13014-015-0465-x

Merlo, 2006, Cancer as an evolutionary and ecological process, Nat Rev Cancer, 6, 924, 10.1038/nrc2013

Attolini, 2009, Evolutionary theory of cancer, Ann N Y Acad Sci, 1168, 23, 10.1111/j.1749-6632.2009.04880.x

Nowell, 1976, The clonal evolution of tumor cell populations, Science, 194, 23, 10.1126/science.959840

Greaves, 2012, Clonal evolution in cancer, Nature, 481, 306, 10.1038/nature10762

Nowak, 2006, Evolutionary dynamics, 10.2307/j.ctvjghw98

Gerlee, 2007, An evolutionary hybrid cellular automaton model of solid tumor growth, J Theor Bio, 246, 583, 10.1016/j.jtbi.2007.01.027

Hummert, 2014, Evolutionary game theory: cells as players, Mol Biosyst, 10, 3044, 10.1039/C3MB70602H

Michor, 2004, Dynamics of cancer progression, Nat Rev Cancer, 4, 197, 10.1038/nrc1295

Hauert, 2005, Game theory and physics, Am J Phys, 73, 405, 10.1119/1.1848514

Hofbauer, 1998, Evolutionary games and population dynamics, 10.1017/CBO9781139173179

Basanta, 2008, A game theoretical perspective on the somatic evolution of cancer, In: selected topics in cancer modeling, 1, 10.1007/978-0-8176-4713-1_5

Ross, 1989, Introduction to probability models: solutions manual for introduction to probability models. Solu, 4

Martincorena, 2015, Somatic mutation in cancer and normal cells, Science, 349, 1483, 10.1126/science.aab4082

Doebeli, 2005, Models of cooperation based on the prisoner's dilemma and the snowdrift game, Ecol Lett, 8, 748, 10.1111/j.1461-0248.2005.00773.x

Doebeli, 2004, The evolutionary origin of cooperators and defectors, Science, 306, 859, 10.1126/science.1101456

Burrell, 2013, The causes and consequences of genetic heterogeneity in cancer evolution, Nature, 501, 338, 10.1038/nature12625

Kendal, 1985, Gompertzian growth as a consequence of tumor heterogeneity, Math Biosci, 73, 103, 10.1016/0025-5564(85)90079-3

Swanton, 2012, Intratumor heterogeneity: evolution through space and time, Cancer Res, 72, 4875, 10.1158/0008-5472.CAN-12-2217

Abbott, 2006, Mathematical models of targeted cancer therapy, Br J Cancer, 95, 1136, 10.1038/sj.bjc.6603310

Bozic, 2013, Evolutionary dynamics of cancer in response to targeted combination therapy, Elife, 2, e00747, 10.7554/eLife.00747

Beckman, 2012, Impact of genetic dynamics and single-cell heterogeneity on development of nonstandard personalized medicine strategies for cancer, Proc Natl Acad Sci, 109, 14586, 10.1073/pnas.1203559109

Foo, 2010, Evolution of resistance to anti-cancer therapy during general dosing schedules, J Theor Biol, 263, 179, 10.1016/j.jtbi.2009.11.022

Basanta, 2012, Exploiting evolution to treat drug resistance: combination therapy and the double bind, Mol Pharm, 9, 914, 10.1021/mp200458e

Liao, 2012, Conceptualizing a tool to optimize therapy based on dynamic heterogeneity, Phys Biol, 9, 065005, 10.1088/1478-3975/9/6/065005

Martin, 1992, Optimal control drug scheduling of cancer chemotherapy, Automatica, 28, 1113, 10.1016/0005-1098(92)90054-J

Loizides, 2015, Model-based tumor growth dynamics and therapy response in a mouse model of de novo carcinogenesis, PLoS One, 10, e0143840, 10.1371/journal.pone.0143840

Gatenby, 2009, A change of strategy in the war on cancer, Nature, 459, 508, 10.1038/459508a

Tannock, 2004, Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer, N Engl J Med, 351, 1502, 10.1056/NEJMoa040720

Spigel, 2011, A phase 2 study of higher dose weekly topotecan in relapsed small-cell lung cancer, Clin Lung Cancer, 12, 187, 10.1016/j.cllc.2011.03.016

Neal, 2013, Discriminating survival outcomes in patients with glioblastoma using a simulation-based, patient-specific response metric, PLoS One, 8, e51951, 10.1371/journal.pone.0051951

Thông tin
Thông tin xuất bản

Cancer Research

Tập 77 Số 23

6717-6728

Thông tin tác giả